Page 24 of 62: studies 231 to 240 of 613, newest first. Back to the ibogaine overview
Journal of Legal Medicine February 28, 2011 Jennifer R. Donnelly
Click to increase image sizeClick to decrease image size
International Anesthesiology Clinics 2011 Clifford Gevirtz 3 citations
Louisiana State University Health Sciences Center New Orleans, Louisiana Reprints: Clifford Gevirtz, MD, MPH, Department of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, e-mail: [email protected]
Drugs and Alcohol Today December 2, 2010 Peter Brackenridge 6 citations
Ibogaine therapy offers a viable alternative to mainstream treatment for opiate addiction. The combination of the addiction‐arresting and fast‐acting properties of ibogaine, with the slow and thoughtful conversation of psychoanalytical psychotherapy is a novel approach to what still remains a difficult condition to overcome.Safer than methadone, ibogaine use is steadily increasing world‐wide,...
Addiction Biology October 1, 2010 Sebastien Carnicella, Dao‐yao He, Quinn V Yowell et al. 49 citations
Ibogaine is a naturally occurring alkaloid that has been reported to decrease various adverse phenotypes associated with exposure to drugs of abuse and alcohol in human and rodent models. Unfortunately, ibogaine cannot be used as a medication to treat addiction because of severe side effects. Previously, we reported that the desirable actions of ibogaine to reduce self-administration of, and...
The international journal of biochemistry & cell biology September 1, 2010 Hugo R Arias, Avraham Rosenberg, Katarzyna M Targowska-Duda et al. 29 citations
The interaction of ibogaine and phencyclidine (PCP) with human (h) alpha3beta4-nicotinic acetylcholine receptors (AChRs) in different conformational states was determined by functional and structural approaches including, radioligand binding assays, Ca2+ influx detections, and thermodynamic and kinetics measurements. The results established that (a) ibogaine inhibits (+/-)-epibatidine-induced...
European Journal of Pharmacology February 10, 2010 Roman Paškulin, Polona Jamnik, Natasa Obermajer et al. 13 citations
Ibogaine has been extensively studied in the last decades in relation to its anti-addictive properties that have been repeatedly reported as being addiction interruptive and craving eliminative. In our previous study we have already demonstrated induction of energy related enzymes in rat brains treated with ibogaine at a dose of 20mg/kg i.p. 24 and 72 h prior to proteomic analysis. In this...
Journal of Pharmaceutical Sciences December 1, 2009 Nicolas Tournier, Pascal André, Sandy Blondeel et al. 14 citations
The (99m)Tc-tricarbonyl core may be used as an ideal tool for gamma-labeling ligands in noninvasive SPECT imaging. However, most (99m)Tc-tricarbonyl-labeled agents have difficulty crossing the blood-brain barrier (BBB). We radiolabeled the neuroactive indole ibogaine with (99m)Tc-tricarbonyl and measured its transport into the mouse brain by in situ brain perfusion. We measured the interactions...
New England Journal of Medicine January 14, 2009 Dianne W. M. Hoelen, Wilko Spiering, Gerlof D. Valk 48 citations
A 31-year-old woman was admitted to the emergency department because of a seizure-like attack after a single 3.5-g dose of ibogaine. ECG showed a severe prolonged-QT interval of 548 msec and ventri...
Medicina September 28, 2008 Asta Kubilienė, Rūta Marksienė, Saulius Kazlauskas et al. 26 citations
OBJECTIVE: To evaluate acute toxic effect of ibogaine and noribogaine on the survival of mice and determine median lethal doses of the substances mentioned. MATERIAL AND METHODS: White laboratory mice were used for the experiments. Ibogaine and noribogaine were administered intragastrically to mice via a stomach tube. Control animals received the same volume of saline. The median lethal dose...
Acta crystallographica. Section E, Structure reports online August 9, 2008 Raoudha Mezghani Jarraya, Amira Bouaziz, Besma Hamdi et al. 1 citation
16-hydroxy-methyl-12-methoxy-ibogamine), C(21)H(28)N(2)O(2), was prepared by reaction of ibogaine with a formaldehyde-acetic acid solution (pH = 4). The crystal structure of this new product, belonging to the iboga indole family, is stabilized by an inter-molecular O-H⋯N hydrogen bond. The identity of the compound was confirmed by one- and two-dimensional NMR spectroscopic techniques.